Miracle celebrity weight loss jab semaglutide causes 'increase in suicidal thoughts', NHS watchdog reveals
The drug, sold as Ozempic or Wegovy, treats diabetes but has been shown in studies to be highly effective at tackling obesity. However, it is feared the drug is causing mental health problems. (Source: the Mail online | Health)
Source: the Mail online | Health - September 30, 2023 Category: Consumer Health News Source Type: news
Brian May ‘horrified’ by method used to prove which Queen song is good for your health
Sir Brian May has slammed the "unjustifiable" method used to prove which of his Queen songs is able to release insulin for diabetics. (Source: Daily Express - Health)
Source: Daily Express - Health - September 30, 2023 Category: Consumer Health News Source Type: news
Are Obesity Drugs for Adolescents Cost-Effective?
(MedPage Today) -- Anti-obesity medications have been making major headlines in the news. From nationwide shortages to publicized usage by celebrities, there is constant buzz about how these medications can lead to weight reduction in a relatively... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 30, 2023 Category: Endocrinology Source Type: news
3 Stocks to Focus on as Demand for Obesity Drugs Booms
The market for obesity and weight management drugs is attracting a lot of interest lately in the United States. Patients are gradually understanding the benefits of obesity drugs like Novo Nordisk’s NVO Wegovy. Meanwhile, Eli Lilly’s LLY Mounjaro (tirzepatide) — already approved for diabetes —…#elilillys #llymounjaro #fda #obese #bmi #pharma #novonordisk #novonordisks #glp1 #cer (Source: Reuters: Health)
Source: Reuters: Health - September 30, 2023 Category: Consumer Health News Source Type: news
Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK ’s Drugs
This week, the European Commission granted marketing approval to AbbVie’s ABBV Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The FDA approved Lilly’s LLY diabetes drug, Jardiance (empagliflozin), for expanded use in chronic kidney disease…#europeancommission #abbvies #fda #lilly #lly #sanofi #dupixent #merck #pah #jnj (Source: Reuters: Health)
Source: Reuters: Health - September 30, 2023 Category: Consumer Health News Source Type: news
Fezolinetant Benefits Women Not Suited for Hormone Therapy
(MedPage Today) -- PHILADELPHIA -- Fezolinetant (Veozah) improved menopause-related vasomotor symptoms in women unsuited or unwilling to take hormone therapy, according to a pooled analysis of two phase III studies.
The analysis of the SKYLIGHT... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 30, 2023 Category: Endocrinology Source Type: news
Triple Therapy Boosts Anaplastic Thyroid Cancer Survival Triple Therapy Boosts Anaplastic Thyroid Cancer Survival
With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 29, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
When to Prescribe Semaglutide? When to Prescribe Semaglutide?
Semaglutide produces significant weight loss in most people with obesity. When should it be prescribed, and what are the pitfalls?Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 29, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
No Benefit to Tight Glucose Control in ICU
(MedPage Today) -- For critically ill patients, strictly controlling glucose to a normal level without early parenteral nutrition neither helped nor harmed outcomes, the randomized TGC-Fast trial showed.
Duration of stay in the intensive care... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 29, 2023 Category: Endocrinology Source Type: news
Support Tool Reduces Hypoglycemia Risk in Type 2 Diabetes Support Tool Reduces Hypoglycemia Risk in Type 2 Diabetes
Shared decision making using a novel clinical-decision support tool led to a reduced risk for hypoglycemic events in a prospective study of 94 high-risk elderly people with type 2 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 29, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Lilly Settles Whistleblower Lawsuit Over Manufacturing Problems Lilly Settles Whistleblower Lawsuit Over Manufacturing Problems
Eli Lilly and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of its diabetes drugs.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 29, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Older Patients With Asymptomatic Primary Hyperparathyroidism Older Patients With Asymptomatic Primary Hyperparathyroidism
When should surgery be considered for older patients with primary hyperparathyroidism who are asymptomatic? Is it time to re-evaluate the current guidelines?Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 29, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
New Insight Into Hyperglycemia Risk With PI3K Inhibitor for Breast Cancer
(MedPage Today) -- Severe hyperglycemia has emerged as a common side effect among patients with PIK3CA-mutated breast cancer treated with the PI3K inhibitor alpelisib (Piqray), especially patients treated outside a clinical trial, a retrospective... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 28, 2023 Category: Endocrinology Source Type: news
Ata 2023 ata 2023
Read clinically focused news coverage of key developments from ATA 2023Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2023 Category: Consumer Health News Tags: None Conference Coverage Source Type: news
Do New Weight Loss Meds Mean the End of Bariatric Surgery? Do New Weight Loss Meds Mean the End of Bariatric Surgery?
The volume of bariatric surgeries may be down, but that doesn ' t render this treatment option any less crucial, surgeon Miguel A. Burch, MD, tells Anne L. Peters, MD.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 28, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
